J&J Beats Q2 Estimates, Raises Full-Year Outlook on Drug Strength
JNJ sits 66% above its 52-week low of $154.8.
Summary
Johnson & Johnson delivered a clean Q2 beat with sales of $25.31B and adjusted EPS of $2.90, topping consensus by about 1% and 2% respectively. The pharmaceutical unit drove the upside, led by Tremfya's 72.5% surge to $2B — well above the $1.74B estimate — as it fills the Stelara patent cliff gap, while Darzalex held steady at $4.2B. Management raised full-year guidance modestly, lifting the sales midpoint to $101.1B and adjusted EPS to $11.68. The one soft spot was MedTech, which missed slightly, with Abiomed sales down 2% after a UK study raised safety questions, though the CFO expects a data-driven recovery next year. Despite the guidance hike, the stock fell, as reported by Barron's.
At the time of this announcement, JNJ was trading at $257.50 on NYSE in the Life Sciences sector, with a market capitalization of approximately $611.1B. The 52-week trading range was $154.80 to $269.43. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Reuters.